Evidence map›Paper›PMID 26728044›Full record

ArticleBMC cancer2016

MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.

Alessandra Tessitore, Germana Cicciarelli, Filippo Del Vecchio, Agata Gaggiano, Daniela Verzella, Mariafausta Fischietti, Valentina Mastroiaco, Antonella Vetuschi, Roberta Sferra, Remo Barnabei and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Effects ofOxidative medicine and cellular longevity · 2022
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Alessandra TessitoreDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. alessandra.tessitore@univaq.it.
Germana CicciarelliDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. ge.c@live.it.
Filippo Del VecchioDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. filippo.delvecchio1@graduate.univaq.it.
Agata GaggianoDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. agata.gaggiano@gmail.com.
Daniela VerzellaDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. danielaverzella@tiscali.it.
Mariafausta FischiettiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. f.fausta@hotmail.it.
Valentina MastroiacoDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. valentina.mastroiaco@graduate.univaq.it.
Antonella VetuschiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. antonella.vetuschi@univaq.it.
Roberta SferraDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. roberta.sferra@univaq.it.
Remo BarnabeiS. Salvatore Hospital, Unit of Laboratory Medicine, L'Aquila, Italy. barnabeiremo@vodafone.it.
Daria CapeceDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. dariacapece@gmail.com.
Francesca ZazzeroniDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. francesca.zazzeroni@univaq.it.
Edoardo AlesseDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio - Coppito 2, 67100, L'Aquila, Italy. edoardo.alesse@univaq.it.
University of L'Aquila · ITSan Salvatore Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Non-alcoholic fatty liver disease (NAFLD) is a frequent chronic liver disorder in developed countries. NAFLD can progress through the more severe non alcoholic steatohepatitis (NASH), cirrhosis and, lastly, HCC. Genetic and epigenetic alterations of coding genes as well as deregulation of microRNAs (miRNAs) activity play a role in HCC development. In this study, the C57BL/6J mouse model was long term high-fat (HF) or low-fat (LF) diet fed, in order to analyze molecular mechanisms responsible for the hepatic damage progression.

methodsMice were HF or LF diet fed for different time points, then plasma and hepatic tissues were collected. Histological and clinical chemistry assays were performed to assess the progression of liver disease. MicroRNAs' differential expression was evaluated on pooled RNAs from tissues, and some miRNAs showing dysregulation were further analyzed at the individual level.

resultsCholesterol, low and high density lipoproteins, triglycerides and alanine aminotransferase increase was detected in HF mice. Gross anatomical examination revealed hepatomegaly in HF livers, and histological analysis highlighted different degrees and levels of steatosis, inflammatory infiltrate and fibrosis in HF and LF animals, demonstrating the progression from NAFLD through NASH. Macroscopic nodules, showing typical neoplastic features, were observed in 20% of HF diet fed mice. Fifteen miRNAs differentially expressed in HF with respect to LF hepatic tissues during the progression of liver damage, and in tumors with respect to HF non tumor liver specimens were identified. Among them, miR-340-5p, miR-484, miR-574-3p, miR-720, whose expression was never described in NAFLD, NASH and HCC tissues, and miR-125a-5p and miR-182, which showed early and significant dysregulation in the sequential hepatic damage process.

conclusionsIn this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified. Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease.

Indexed as

AnimalsCarcinoma, HepatocellularCell Line, TumorCholesterolDiet, High-FatDisease Models, AnimalDisease ProgressionGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMiceMicroRNAsNon-alcoholic Fatty Liver DiseaseTriglyceridesCholesterolMicroRNAsTriglycerides

Identifiers

PMID26728044
PMCPMC4700747
OpenAlexW2222334274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.